Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study

Kimberly E. Hanson, Christopher Pfeiffer, Erika D. Lease, Alfred H. Balch, Aimee K. Zaas, John R. Perfect, Barbara D. Alexander

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Invasive candidiasis (IC) is a devastating disease. While prompt antifungal therapy improves outcomes, empiric treatment based on the presence of fever has little clinical impact. Β-D-Glucan (BDG) is a fungal cell wall component detectable in the serum of patients with early invasive fungal infection (IFI). We evaluated the utility of BDG surveillance as a guide for preemptive antifungal therapy in at-risk intensive care unit (ICU) patients. Methods: Patients admitted to the ICU for ≥3 days and expected to require at least 2 additional days of intensive care were enrolled. Subjects were randomized in 3:1 fashion to receive twice weekly BDG surveillance with preemptive anidulafungin in response to a positive test or empiric antifungal treatment based on physician preference. Results: Sixty-four subjects were enrolled, with 1 proven and 5 probable cases of IC identified over a 2.5 year period. BDG levels were higher in subjects with proven/probable IC as compared to those without an IFI (117 pg/ml vs. 28 pg/ml; p<0.001). Optimal assay performance required 2 sequential BDG determinations of ≥80 pg/ml to define a positive test (sensitivity 100%, specificity 75%, positive predictive value 30%, negative predictive value 100%). In all, 21 preemptive and 5 empiric subjects received systemic antifungal therapy. Receipt of preemptive antifungal treatment had a significant effect on BDG concentrations (p< 0.001). Preemptive anidulafungin was safe and generally well tolerated with excellent outcome. Conclusions: BDG monitoring may be useful for identifying ICU patients at highest risk to develop an IFI as well as for monitoring treatment response. Preemptive strategies based on fungal biomarkers warrant further study. Trial Registration: Clinical Trials.gov NCT00672841.

Original languageEnglish (US)
Article numbere42282
JournalPloS one
Volume7
Issue number8
DOIs
StatePublished - Aug 6 2012

Fingerprint

anidulafungin
Invasive Candidiasis
Intensive care units
candidiasis
glucans
Intensive Care Units
monitoring
therapeutics
Monitoring
Biomarkers
infection
Assays
cell wall components
Therapeutics
physicians
Cells
fever
clinical trials
biomarkers
testing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients : A randomized pilot study. / Hanson, Kimberly E.; Pfeiffer, Christopher; Lease, Erika D.; Balch, Alfred H.; Zaas, Aimee K.; Perfect, John R.; Alexander, Barbara D.

In: PloS one, Vol. 7, No. 8, e42282, 06.08.2012.

Research output: Contribution to journalArticle

Hanson, Kimberly E. ; Pfeiffer, Christopher ; Lease, Erika D. ; Balch, Alfred H. ; Zaas, Aimee K. ; Perfect, John R. ; Alexander, Barbara D. / Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients : A randomized pilot study. In: PloS one. 2012 ; Vol. 7, No. 8.
@article{d392ba8b217a4d0eae64465b625567cf,
title = "Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study",
abstract = "Background: Invasive candidiasis (IC) is a devastating disease. While prompt antifungal therapy improves outcomes, empiric treatment based on the presence of fever has little clinical impact. Β-D-Glucan (BDG) is a fungal cell wall component detectable in the serum of patients with early invasive fungal infection (IFI). We evaluated the utility of BDG surveillance as a guide for preemptive antifungal therapy in at-risk intensive care unit (ICU) patients. Methods: Patients admitted to the ICU for ≥3 days and expected to require at least 2 additional days of intensive care were enrolled. Subjects were randomized in 3:1 fashion to receive twice weekly BDG surveillance with preemptive anidulafungin in response to a positive test or empiric antifungal treatment based on physician preference. Results: Sixty-four subjects were enrolled, with 1 proven and 5 probable cases of IC identified over a 2.5 year period. BDG levels were higher in subjects with proven/probable IC as compared to those without an IFI (117 pg/ml vs. 28 pg/ml; p<0.001). Optimal assay performance required 2 sequential BDG determinations of ≥80 pg/ml to define a positive test (sensitivity 100{\%}, specificity 75{\%}, positive predictive value 30{\%}, negative predictive value 100{\%}). In all, 21 preemptive and 5 empiric subjects received systemic antifungal therapy. Receipt of preemptive antifungal treatment had a significant effect on BDG concentrations (p< 0.001). Preemptive anidulafungin was safe and generally well tolerated with excellent outcome. Conclusions: BDG monitoring may be useful for identifying ICU patients at highest risk to develop an IFI as well as for monitoring treatment response. Preemptive strategies based on fungal biomarkers warrant further study. Trial Registration: Clinical Trials.gov NCT00672841.",
author = "Hanson, {Kimberly E.} and Christopher Pfeiffer and Lease, {Erika D.} and Balch, {Alfred H.} and Zaas, {Aimee K.} and Perfect, {John R.} and Alexander, {Barbara D.}",
year = "2012",
month = "8",
day = "6",
doi = "10.1371/journal.pone.0042282",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients

T2 - A randomized pilot study

AU - Hanson, Kimberly E.

AU - Pfeiffer, Christopher

AU - Lease, Erika D.

AU - Balch, Alfred H.

AU - Zaas, Aimee K.

AU - Perfect, John R.

AU - Alexander, Barbara D.

PY - 2012/8/6

Y1 - 2012/8/6

N2 - Background: Invasive candidiasis (IC) is a devastating disease. While prompt antifungal therapy improves outcomes, empiric treatment based on the presence of fever has little clinical impact. Β-D-Glucan (BDG) is a fungal cell wall component detectable in the serum of patients with early invasive fungal infection (IFI). We evaluated the utility of BDG surveillance as a guide for preemptive antifungal therapy in at-risk intensive care unit (ICU) patients. Methods: Patients admitted to the ICU for ≥3 days and expected to require at least 2 additional days of intensive care were enrolled. Subjects were randomized in 3:1 fashion to receive twice weekly BDG surveillance with preemptive anidulafungin in response to a positive test or empiric antifungal treatment based on physician preference. Results: Sixty-four subjects were enrolled, with 1 proven and 5 probable cases of IC identified over a 2.5 year period. BDG levels were higher in subjects with proven/probable IC as compared to those without an IFI (117 pg/ml vs. 28 pg/ml; p<0.001). Optimal assay performance required 2 sequential BDG determinations of ≥80 pg/ml to define a positive test (sensitivity 100%, specificity 75%, positive predictive value 30%, negative predictive value 100%). In all, 21 preemptive and 5 empiric subjects received systemic antifungal therapy. Receipt of preemptive antifungal treatment had a significant effect on BDG concentrations (p< 0.001). Preemptive anidulafungin was safe and generally well tolerated with excellent outcome. Conclusions: BDG monitoring may be useful for identifying ICU patients at highest risk to develop an IFI as well as for monitoring treatment response. Preemptive strategies based on fungal biomarkers warrant further study. Trial Registration: Clinical Trials.gov NCT00672841.

AB - Background: Invasive candidiasis (IC) is a devastating disease. While prompt antifungal therapy improves outcomes, empiric treatment based on the presence of fever has little clinical impact. Β-D-Glucan (BDG) is a fungal cell wall component detectable in the serum of patients with early invasive fungal infection (IFI). We evaluated the utility of BDG surveillance as a guide for preemptive antifungal therapy in at-risk intensive care unit (ICU) patients. Methods: Patients admitted to the ICU for ≥3 days and expected to require at least 2 additional days of intensive care were enrolled. Subjects were randomized in 3:1 fashion to receive twice weekly BDG surveillance with preemptive anidulafungin in response to a positive test or empiric antifungal treatment based on physician preference. Results: Sixty-four subjects were enrolled, with 1 proven and 5 probable cases of IC identified over a 2.5 year period. BDG levels were higher in subjects with proven/probable IC as compared to those without an IFI (117 pg/ml vs. 28 pg/ml; p<0.001). Optimal assay performance required 2 sequential BDG determinations of ≥80 pg/ml to define a positive test (sensitivity 100%, specificity 75%, positive predictive value 30%, negative predictive value 100%). In all, 21 preemptive and 5 empiric subjects received systemic antifungal therapy. Receipt of preemptive antifungal treatment had a significant effect on BDG concentrations (p< 0.001). Preemptive anidulafungin was safe and generally well tolerated with excellent outcome. Conclusions: BDG monitoring may be useful for identifying ICU patients at highest risk to develop an IFI as well as for monitoring treatment response. Preemptive strategies based on fungal biomarkers warrant further study. Trial Registration: Clinical Trials.gov NCT00672841.

UR - http://www.scopus.com/inward/record.url?scp=84864702571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864702571&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0042282

DO - 10.1371/journal.pone.0042282

M3 - Article

C2 - 22879929

AN - SCOPUS:84864702571

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e42282

ER -